(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback